期刊文献+

慢性肝病患者血清MMP-9的检测及临床意义

The change of serum Matrix Metalloproteinase-9 in chronic liver disease
下载PDF
导出
摘要 目的 研究基质金属蛋白酶 9(MMP 9)在慢性肝病患者肝纤维化过程中的表达和动态变化。方法 用酶标法检测 75例慢性乙型病毒性肝炎和 40例乙肝后肝硬化患者血清中MMP 9浓度。结果 血清MMP 9浓度在慢性肝病患者肝纤维化过程中逐渐升高 ,与正常对照组比较有显著性意义 (P <0 .0 1) ;其中轻度患者的MMP 9与中度、重度、肝硬化之间 ,肝硬化与中度、重度之间两两比较有显著性差异 (P <0 .0 5或P <0 .0 1)。结论 血清MMP 9在慢性肝病患者肝纤维化过程中可能起促进作用 。 ObjectiveTo investigate the dynamic change and expression of Matrix Metalloproteinase-9(MMP-9) in patients with ch ronic hepatitis B(CHB) and liver cirrhosis(LC).MethodsSerum MMP -9 was detected by ELISA in 75 patients with CHB and 40 patients with LC and 2 0 healthy persons.ResultsSerum MMP-9 increased in CHB and LC.There were significan t differences between patients with chronic liver disease and control group ( P<0.01).MMP-9 levels in severe degrees of CHB and LC were higher than those in mild and moderate degrees of CHB(P<0.05/0.01) and seru m MMP-9 levels in LC were notably higher than those in severe degrees of CHB to o.ConclusionSerum MMP-9 levels increase in CHB and LC.It may par ticipate in the development of hepatic fibrosis and can be used as diagnostic in dex for hepatic fibrosis in chronic liver diseases.
出处 《胃肠病学和肝病学杂志》 CAS 2003年第6期578-579,共2页 Chinese Journal of Gastroenterology and Hepatology
关键词 慢性肝病 血清 MMP-9 临床意义 肝纤维化 细胞外基质 Matrix Metalloproteinase-9 Hepatic fibros is
  • 相关文献

参考文献7

二级参考文献12

  • 1赵静波,王泰龄,张道明,张晶.嗜酒者肝脏病变的形态学研究[J].中华病理学杂志,1994,23(1):14-16. 被引量:21
  • 2[1]Matrisian LM. The matrix- degrading metalloproteinases [J].Bioessays, 1992, 14:455-463.
  • 3[2]Takino T, Sato H, Shinagawa A, et al. Identification of the second membrane- type matrix metalloproteriaiesgene from a human placente cDNA[J]. J Biol Chem, 1995, 270:23013 - 23020.
  • 4[3]Murawaki Y, Ikuta Y, Kawasaki H. Serum matrix metalloproteinawe-1 in patients with chronic viral hepatitis[J] .J Gastroenterol Hepatol, 1999, 14(2):138- 145.
  • 5[4]Murawaki Y, Ikuta Y, Idobe Y, et al. Tissue inhibitor of metalloproteinase - 1 in the liver of patients with chronic liver disease[ J]. J Hepatol, 1997, 26(6): 1213 - 1219.
  • 6[5]Murawaki Y, Ikuta Y, Okamoto K. Serum matrix metalloproteinase - 3 (stromelysin - 1 ) concentration in patients with chronic liver disease[J] .J Hepatol, 1999, 31(3) :474- 481.
  • 7[6]Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix metalloproteinase - 2 and tissue inhibitor of metalloproteinase- 1 as serum markers of fibrosis in patients with chronic hepatitis C Relationship to interferon response[ J]. J Hepatol, 1997, 26(3 ): 574 -583.
  • 8[7]Nakamura - T, Ushiyama - C, Suzuki - S. Effect of plasma exchange on serum tissue inhibitor of metalloproteinase 1 and cytokine concentrations in patients with fulminant hepatitis[J]. Blood Purif,2000, 18(11):50-54.
  • 9Arthur MJP.Degradation of matrix proteins in Liver fibrosis[].Pathology Research and Practice.1994
  • 10Hayasaka A,Suzuki N,Fujimoto N.Elevated plasma levels of ma-trix metalloproteinase - 9 (92 - kda gelatinase B) in HepatocellularCarcinoma[].Hepatology.1996

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部